Phase I study of the safety and biological activity of intraperitoneal IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer administered in combination with standard neoadjuvant chemotherapy in patients with newly diagnosed ovarian cancer.

Premal H Thaker,William Hampton Bradley,Kathleen N Moore,Charles A Leath,Nicholas Borys,Khursheed Anwer,Ronald David Alvarez

doi:10.1200/jco.2016.34.15_suppl.tps5605

Phase I study of the safety and biological activity of intraperitoneal IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer administered in combination with standard neoadjuvant chemotherapy in patients with newly diagnosed ovarian cancer.

Premal H Thaker, William Hampton Bradley + Show 5 more

https://doi.org/10.1200/jco.2016.34.15_suppl.tps5605

Copy DOI

Export

Save

Cite

Journal: Journal of Clinical Oncology	Publication Date: May 20, 2016
Citations: 1

Affiliation: Washington University in St. Louis, Medical College of Wisconsin, University of Oklahoma Health Sciences Center, University of Alabama at Birmingham, Celsion (United States)

#Ovarian Cancer #Fallopian #Standard Neoadjuvant Chemotherapy #Neoadjuvant Chemotherapy In Patients #Neoadjuvant #Gynecol Oncol #Progression-free Survival #Complete Response #Primary Peritoneal #Primary Peritoneal Cancer Patients

Abstract
Full-Text
Similar Papers

Abstract

Listen

TPS5605Background: This phase 1 study (NCT02480374) evaluates the use of weekly intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in combination with dose-dens...

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

Phase I study of the safety and biological activity of intraperitoneal IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer administered in combination with standard neoadjuvant chemotherapy in patients with newly diagnosed ovarian cancer.